12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

INCB13739: Phase IIb data

Data from a double-blind Phase IIb trial in 302 patients showed that the 2 highest doses (100 and 200 mg) of INCB13739 met the primary endpoint of significantly decreased HbA1c vs. placebo at 12 weeks (0.47% and 0.56%,...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >